Stay updated with breaking news from Servier Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2...
Private drug developer Servier Group said on Sunday its experimental brain cancer treatment has considerably slowed the progession of a type of brain tumor, a positive in a field that has not seen... | June 4, 2023
(Reuters) - Private drug developer Servier Group said on Sunday its experimental brain cancer treatment has considerably slowed the progession of a ty...
Kansascity.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kansascity.com Daily Mail and Mail on Sunday newspapers.
A French drug developer’s experimental therapy slowed the progression of a type of brain cancer by more than 16 months on average, results that could lead to one of the